An analysis of the effect of Oxaliplatin in inducing immunogenetic celldeath and improving the efficacy of checkpoint inhibitor on SGC-7901

Abstract

Previous studies demonstrated Oxaliplatin, a derivative of Cisplatin, to have anti-cancer properties in a Lewis LungCarcinoma (LLC). It can induce immunogenic cell death (ICD) in tumor cells and co-administrate with checkpointinhibitors to improve the therapeutic efficacy. This study aims to investigate Oxaliplatin’s effect on a different gastriccarcinoma, SGC-7901, and analyze the therapeutic efficacy of its co-administration with the checkpoint inhibitor. Toevaluate the immunogenic cell death (ICD) induced by Oxaliplatin in SGC-7901, flow cytometry, HMGB1, ATP release,and immunoblotting were conducted. The effectiveness of Oxaliplatin was analyzed using a vaccination approach andsubcutaneous tumor models to observe tumour regression. PD-L1 mRNA and protein levels in SGC-7901 were alsoexamined. The therapeutic efficacy of Oxaliplatin in murine lung tumor models will be enhanced by co-administeringwith aPD-L1. Cisplatin will be employed as a positive control, while PBS will be a negative control. The result of thestudy will provide important insight into the experimental effectiveness of Oxaliplatin in SGC-7901, it also sets thebasis for future experimental, preclinical, and clinical studies of the drug. Future studies should focus on practicing theactual experiment on the experimental effectiveness of Oxaliplatin in SGC-7901 and look for the applicability of theeffectiveness of Oxaliplatin on other tumor cells.